Actively Recruiting
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Led by University of Oklahoma · Updated on 2026-03-05
13
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
Sponsors
U
University of Oklahoma
Lead Sponsor
D
Dendreon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
CONDITIONS
Official Title
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men 18 years of age or older
- Prostate cancer with a history of metastasis
- Candidates with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 6 months
You will not qualify if you...
- Previous treatment with Sipuleucel-T (Provenge�ae)
- Other known cancers likely to need treatment within 6 months after registration
- Need for systemic immunosuppressive therapy greater than 10mg Prednisone daily or equivalent
- History of allergic reactions to substances similar to Sipuleucel-T or GM-CSF
- Infection requiring antibiotics within 1 week before registration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Oklahoma Health Sciences Center, Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73114
Actively Recruiting
Research Team
L
Lead Onco Nurse
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here